---
title: "Jazz Pharmaceuticals Q2 2026 earnings preview"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294559582.md"
description: "Jazz Pharmaceuticals (JAZZ) will report Q2 2026 earnings on August 3rd after market close. Consensus estimates project EPS of $6.18, up 174.9% year-over-year, and revenue of $1.11 billion, a 5.7% increase. Historically, the company has beaten both EPS and revenue estimates in 75% of quarters over the past two years."
datetime: "2026-07-31T21:54:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294559582.md)
  - [en](https://longbridge.com/en/news/294559582.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294559582.md)
generator: "portal-rs"
---

# Jazz Pharmaceuticals Q2 2026 earnings preview

Jazz Pharmaceuticals (JAZZ) is scheduled to announce Q2 earnings results on Monday, August 3rd, after market close. The consensus EPS estimate is $6.18 (+174.9% Y/Y), and the consensus revenue estimate is $1.11B (+5.7% Y/Y). Over the last 2 years, JAZZ has beaten EPS estimates 75% of the time and has beaten revenue estimates 75% of the time. Over t...

### Related Stocks

- [JAZZ.US](https://longbridge.com/en/quote/JAZZ.US.md)

## Related News & Research

- [Jazz Pharmaceuticals (JAZZ) Could Be 13% Undervalued On FDA Approval Of Ziihera](https://longbridge.com/en/news/297431759.md)
- [Jazz Pharmaceuticals Raises $1.25 Billion Via 1.875% Exchangeable Notes Due 2032](https://longbridge.com/en/news/297565380.md)
- [Jazz Pharmaceuticals prices upsized USD 1.1 billion exchangeable senior notes offering due 2032](https://longbridge.com/en/news/297122954.md)
- [Jazz Pharmaceuticals unit launches private offering of $1 billion exchangeable senior notes due 2032](https://longbridge.com/en/news/297563972.md)
- [These Analysts Increase Their Forecasts On Jazz Pharmaceuticals](https://longbridge.com/en/news/297066303.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**